EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

More on GLP-1 and incretin signalling

• Diabetes, Obesity & Metabolism·8 Oct 2026

  Diabetes drug class linked to slightly less frailty progression

  

• Diabetes & Vascular Disease Research·4 Oct 2026

  SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

• Nature Medicine·4 Oct 2026

  Semaglutide may protect kidneys by reducing vascular resistance

  

• Lancet·4 Oct 2026

  Retatrutide reduces bodyweight in obesity and type 2 diabetes